American Society of Nephrology

The American Society of Nephrology is a professional organization represented in the evidence as a co-sponsor of the consensus process governing transplant choices for patients with hepatitis C and cirrhosis. Its clearest documented intervention concerns the boundary between kidney-alone transplantation and simultaneous liver–kidney transplantation, a decision with consequences for operative risk, organ allocation, and long-term survival.

Institutional Role and Scope

The American Society of Nephrology appears alongside the American Society of Transplantation, the American Society of Transplant Surgeons, and the United Network for Organ Sharing as a co-sponsoring body of a consensus conference on simultaneous liver–kidney transplantation. The evidence does not assign the organization a bedside treatment role, nor does it describe a particular individual acting on its behalf. Instead, it places the organization within a multidisciplinary policy network that translates clinical evidence about hepatic reserve and portal hypertension into transplant-listing recommendations.

That institutional position is especially important because HCV-infected kidney-transplant candidates may have serious but clinically compensated liver disease. Between 10% and 25% of candidates have advanced liver injury, including stage 3 or stage 4 fibrosis or cirrhosis, when assessed by biopsy. Many remain well compensated and would not otherwise be suspected of harboring substantial hepatic damage. The organization’s documented relevance therefore lies in helping address a classification problem: which patients can safely receive a kidney alone, and which require consideration for a combined liver–kidney procedure.

Consensus on Transplant Listing

The consensus process associated with the American Society of Nephrology proposed portal hypertension as a central criterion for choosing between kidney-alone transplantation and simultaneous liver–kidney transplantation in patients with well-compensated cirrhosis. Its specific recommendation was that patients with a wedge hepatic vein pressure below 10 mm Hg should be listed for kidney transplantation alone, although the evidence explicitly notes that this threshold remained to be validated in practice.

The framework was not limited to a single numerical measurement in every clinical program. Additional criteria described in the evidence included the absence of varices on endoscopy and a platelet count above 120 × 10³/µl when considering kidney-alone transplantation. These measures function as practical indicators of portal-hypertension burden and residual hepatic reserve. Established or decompensated cirrhosis, by contrast, was generally considered a reason to refer the patient to a liver-transplant team for evaluation of combined transplantation.

Evidence and Clinical Tensions

The organization’s consensus role sits within a field marked by substantial uncertainty. Kidney transplantation in a cirrhotic patient carries increased perioperative morbidity and mortality because of limited physiologic reserve and nutritional status, as well as greater susceptibility to infectious and metabolic complications and poorer longer-term survival. A retrospective study of 772 cirrhotic patients undergoing major surgery reported 30-day mortality of 5.7% among those with the least severe cirrhosis by MELD score, but the usefulness of MELD in kidney-transplant patients was uncertain because serum creatinine is a major component of the score and only about one fifth of the study population had viral hepatitis.

Long-term transplant evidence was also limited. No definitive studies had established outcomes for HCV-infected kidney recipients with cirrhosis documented by pretransplant liver biopsy. In one single-center series, only 26% of the small group with pretransplant cirrhosis remained alive 10 years after transplantation. These limitations explain why the consensus recommendation was framed as a decision aid rather than an absolute rule: portal-pressure criteria offered a structured way to stratify candidates, but their real-world validity and the durability of kidney-alone transplantation in this population remained unresolved.

Diagnostic Framework Surrounding the Policy

The transplant decisions addressed by the consensus process depend on distinguishing exposure from active infection. HCV infection is initially identified through anti-HCV antibodies, while active infection is established by detecting HCV RNA in serum with sensitive molecular assays. Chronic infection requires both anti-HCV positivity and HCV RNA positivity, with infection persisting for more than six months in the chronic-disease definition used in the evidence.

Once active infection is identified, assessment must cover both hepatic and extrahepatic injury. Liver biopsy remained the most reliable method for staging fibrosis in kidney-transplant candidates, despite efforts to use noninvasive measures. Biochemical scores and elastometry with FibroScan can reduce the need for biopsy in some settings, but the KDIGO workgroup recommended percutaneous liver biopsy for all HCV-infected patients being evaluated for kidney transplantation because available noninvasive tests did not yet provide equivalent accuracy and reliability.

This diagnostic precision matters beyond liver staging. HCV can produce extrahepatic disease, including mixed cryoglobulinemia and immune-complex glomerulonephritis. In renal allografts, HCV-associated membranoproliferative glomerulonephritis may present with hypertension, microscopic hematuria, proteinuria, renal dysfunction, or nephrotic syndrome. The broader clinical context also includes a documented association between HCV and reduced survival in dialysis patients: a meta-analysis of 11,589 patients estimated an adjusted relative risk of all-cause mortality of 1.34, while liver-related mortality was substantially higher among anti-HCV-positive patients.

Broader Nephrology Significance

The American Society of Nephrology’s documented contribution illustrates how nephrology organizations participate in decisions that extend beyond renal replacement alone. HCV infection affects diagnosis, dialysis survival, antiviral treatment, renal-allograft pathology, and the safety of immunosuppression. After kidney transplantation, interferon-based treatment was associated with poor tolerance and an increased risk of graft rejection; a meta-analysis of renal-transplant patients reported a sustained virologic response of 18% and a dropout rate of 35%, with graft dysfunction accounting for most treatment interruptions. Such risks reinforce the importance of resolving liver disease and treatment strategy before transplantation whenever possible.

The consensus structure also reflects the need to balance competing harms rather than treat one organ in isolation. Kidney-alone transplantation may spare a patient the complexity and scarcity of a combined graft, but it can expose a cirrhotic recipient to unacceptable hepatic and perioperative risk. Simultaneous liver–kidney transplantation may address both organs but requires stronger justification and appropriate allocation of scarce organs. Within that tension, the American Society of Nephrology functions as part of the professional infrastructure that converts incomplete evidence into operational criteria, while leaving room for clinical judgment, validation, and revision as outcome data accumulate.